| Literature DB >> 28860766 |
Sameh Samir Ali1,2, Reda Morsy3,4, Nessma Ahmed El-Zawawy2, Mervat F Fareed5,6, Mohamed Yaser Bedaiwy2.
Abstract
Increasing of multidrug resistance (MDR) remains an intractable challenge for burn patients. Innovative nanomaterials are also in high demand for the development of new antimicrobial biomaterials that inevitably have opened new therapeutic horizons in medical approaches and lead to many efforts for synthesizing newEntities:
Keywords: anti-inflammatory; antimicrobial; burn wound infections; co-precipitation method; metal oxides nanoparticles; multidrug resistance
Mesh:
Substances:
Year: 2017 PMID: 28860766 PMCID: PMC5573044 DOI: 10.2147/IJN.S141201
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Antimicrobial activity of ZnO2-NPs against MDR Pseudomonas aeruginosa and Aspergillus niger strains
| Strain number | Diameter of inhibition zone (mm)
| MIC | MBC | MFC | AMP | ||
|---|---|---|---|---|---|---|---|
| Concentrations of ZnO2-NPs (µg/mL)
| |||||||
| 50 | 100 | 200 | |||||
| PA1 | 7.0±0.0a | 7.0±0.0a | 8.0±0.0a | 50 | 100 | ND | AX, CTX, CAZ, CRO, ATM, SXT, TE, C, K, CT |
| PA2 | 0.0±0.0b | 0.0±0.0b | 0.0±0.0b | ND | ND | ND | AX, CTX, CAZ, FEP, CRO, ATM, CIP, SXT, TE, C, TOB, K |
| PA3 | 9.0±1.0c | 10.0±1.0c | 11.0±1.0c | 50 | 100 | ND | AX, CTX, CAZ, ATM, CIP, SXT, TE, C, K, CT |
| PA4 | 7.0±1.0a | 12.0±0.0d | 15.0±2.0d | 25 | 50 | ND | AX, CAZ, FEP, CRO, CIP, SXT, CN, TOB, K, CT |
| PA5 | 0.0±0.0b | 0.0±0.0b | 0.0±0.0b | ND | ND | ND | AX, CTX, CAZ, FEP, CRO, CIP, SXT, TE, K |
| PA6 | 12.0±2.0d | 17.0±2.0e | 21.0±1.0e | 6.25 | 12.5 | ND | AX, CTX, CAZ, CRO, ATM, CIP, SXT, TE, CN, TOB, K, CT |
| PA7 | 9.0±0.0c | 13.0±0.0d | 18.0±0.0f | 6.25 | 12.5 | ND | AX, CTX, CAZ, CRO, ATM, IPM, SXT, TE, C, TOB, CT |
| PA8 | 10.0±1.0e | 11.0±1.0d | 15.0±1.0d | 25 | 50 | ND | AX, CTX, CAZ, FEP, CRO, ATM, CIP, SXT, C, K, CT |
| PA9 | 7.0±0.0a | 9.0±0.0f | 12.0±0.0c | 50 | 100 | ND | AX, CAZ, FEP, ATM, CRO, IPM, CIP, SXT, C, CN, TOB, K, CT |
| PA10 | 0.0±0.0b | 0.0±0.0b | 0.0±0.0b | ND | ND | ND | AX, CTX, CAZ, FEP, ATM, CIP, SXT, TE, C, CN, TOB, K, CT |
| PA11 | 0.0±0.0b | 7.0±0.0a | 10.0±1.0c | 50 | 100 | ND | AX, CTX, CAZ, FEP, CRO, ATM, CIP, SXT, TE, TOB, K, CT |
| AN1 | 20.0±2.0f | 25.0±1.0g | 35.0±3.0g | 6.25 | ND | 12.5 | ITC, MIZ, FLC, NYT, TRB |
| AN2 | 10.0±0.0e | 16.0±1.0e | 22.0±2.0e | 12.5 | ND | 25 | ITC, CLT, FLC, MCFG, TRB |
| AN3 | 0.0±0.0b | 0.0±0.0b | 0.0±0.0b | 0.0 | ND | ND | AMB, ITC, MIZ, FLC, MCFG, TRB |
| AN4 | 30.0±3.0g | 30.0±3.0h | 40.0±1.0h | 6.25 | ND | 12.5 | ITC, CLT, FLC, MCFG, NYT, TRB |
| AN5 | 20.0±2.0f | 25.0±2.0g | 30.0±2.0i | 6.25 | ND | 12.5 | AMB, ITC, CLT, MIZ, FLC, TRB |
| AN6 | 11.0±0.0h | 11.0±0.0d | 18.0±0.0f | 25 | ND | 50 | ITC, CLT, MIZ, FLC, NYT, TRB |
| AN7 | 14.0±2.0i | 20.0±1.0i | 25.0±1.0j | 6.25 | ND | 12.5 | AMB, ITC, CLT, FLC, MCFG, NYT, TRB |
| AN8 | 9.0±0.0c | 16.0±1.0e | 20.0±0.0e | 25 | ND | 50 | AMB, ITC, MIZ, FLC, TRB |
| AN9 | 18.0±2.0j | 22.0±2.0i | 32.0±2.0g,i | 6.25 | ND | 12.5 | ITC, CLT, MIZ, FLC, MCFG, TRB |
| AN10 | 14.0±1.0i | 20.0±1.0i | 28.0±1.0j | 25 | ND | 50 | AMB, ITC, CLT, MIZ, FLC, NYT, TRB |
| AN11 | 0.0±0.0b | 0.0±0.0b | 0.0±0.0b | 0.0 | ND | ND | ITC, CLT, FLC, MCFG, NYT, TRB |
| ANOVA | |||||||
| F | 0.133 | 0.0349 | 0.001 | ||||
| | 0.875 | 0.965 | 0.998 | ||||
Notes: Values are the mean of three replicates ± SD. Means with the same letters in the same column show the insignificant difference (P≤0.05).
Abbreviations: AMB, amphotericin; AMP, antimicrobial profile; AN, Aspergillus niger; ANOVA, analysis of variance; ATM, aztreonam; AX, amoxicillin; C, chloramphenicol; CAZ, ceftazidime; CIP, ciprofloxacin; CLT, clotrimazole; CN, gentamicin; CRO, ceftriaxone; CT, colistin sulfate; CTX, cefotaxime; FEP, cefepime; FLC, fluconazole; IPM, imipenem; ITC, itraconazole; K, kanamycin; MBC, minimum bactericidal concentration; MCFG, micfungin; MDR, multidrug resistance; MFC, minimum fungicidal concentration; MIC, minimum inhibitory concentration; MIZ, miconazole; NPs, nanoparticles; ND, not detected; NYT, nystatin; PA, Pseudomonas aeruginosa; SXT, cotrimoxazole; TE, tetracycline; TOB, tobramycin; TRB, terbinafine.
Figure 1X-ray diffraction pattern of the synthetic ZnO2-NPs.
Figure 2Fourier transformed infrared spectrum of the synthetic ZnO2-NPs.
Figure 3Transmission electron microscopy image of the synthetic ZnO2-NPs.
Figure 4Thermogravimetric analysis and differential scanning calorimetric curves of the synthetic ZnO2-NPs.
Figure 5Ultraviolet spectra of the synthetic ZnO2-NPs.
Figure 6Time course of elastase (A) and keratinase (B) production by PA6 strain (blue line) and AN4 strain (red line).
Abbreviations: AN, Aspergillus niger; PA, Pseudomonas aeruginosa.
Anti-elastase and anti-keratinase activities of ZnO2-NPs
| Concentration of ZnO2-NPs (µg/mL) | Enzyme activity (U/mL)
| |||
|---|---|---|---|---|
| Elastase
| Keratinase
| |||
| PA6 | AN4 | PA6 | AN4 | |
| 6.25 | 28.0±1.0a | 31.0±1.0a | 25.0±1.0a | 37.0±2.0a |
| 12.5 | 23.0±2.0b | 21.0±1.0b | 13.0±1.0b | 35.0±1.0b |
| 25 | 18.0±1.0c | 14.0±0.0c | 9.0±0.0c | 26.0±0.0c |
| 50 | 6.0±0.0d | 8.0±0.0d | 5.0±0.0d | 20.0±1.0d |
| 100 | 1.0±0.0e | 2.0±0.0e | 0.0±0.0e | 12.0±0.0e |
| 200 | 0.0±0.0f | 0.0±0.0f | 0.0±0.0e | 0.0±0.0e |
| ANOVA | ||||
| F | 0.002 | 0.001 | 0.002 | 0.007 |
| | 0.997 | 0.998 | 0.997 | 0.992 |
Notes: Values are the mean of three replicates ± SD. Means with the same letters in the same column showed the insignificant difference (P≤0.05).
Abbreviations: AN, Aspergillus niger; ANOVA, analysis of variance; NPs, nanoparticles; PA, Pseudomonas aeruginosa.
Anti-inflammatory effect of ZnO2-NPs compared to aspirin
| Concentration (µg/mL) | Inhibitory percentage of albumin denaturation
| Percentage of membrane stabilization activity
| Inhibitory percentage of proteinase activity
| |||
|---|---|---|---|---|---|---|
| ZnO2-NPs | Aspirin | ZnO2-NPs | Aspirin | ZnO2-NPs | Aspirin | |
| 100 | 25.0±0.0a | 40.1±0.7a | 28.0±1.0a | 42.3±1.1a | 30.0±0a | 58.0±1.0a |
| 250 | 40.0±2.0b | 41.7±1.1a,b | 45.0±1.0b | 68.6±1.5b | 47.0±2b | 68.7±2.2b |
| 500 | 57.0±3.0c | 45.7±2.5b | 62.0±2.0c | 71.3±2.0b | 58.0±2c | 81.5±0.5c |
| 1,000 | 82.0±1.0d | 71.1±1.0c | 73.0±1.0d | 74.9±0.5b,c | 80.0±1d | 83.7±0.4c |
| 2,000 | 90.0±3.0d | 85.3±2.1d | 81.0±3.0e | 82.1±2.2c | 89.0±2e | 89.2±1.9c |
| ANOVA | ||||||
| F | 0.0008 | 0.0004 | 0.0156 | 0.045 | 0.0003 | 0.0193 |
| | 0.9991 | 0.9995 | 0.9845 | 0.9561 | 0.9996 | 0.9808 |
Notes: Values are the mean of three replicates ± SD. Means with the same letters in the same column showed the insignificant difference (P≤0.05).
Abbreviations: ANOVA, analysis of variance; NPs, nanoparticles.
Figure 7Histopathological examination of burn wounds after 7 days (A, C) and 21 days (B, D) after treatment protocols with ZnO2-NPs (A, B) compared to silver sulfadiazine (C, D).
Note: Magnification power (200×).
Abbreviation: NPs, nanoparticles.
In vivo evaluation of inflammation, ulcer formation, and re-epithelialization in different rabbit groups
| Rabbit group (n=6) | Inflammation | Surface ulceration | Re-epithelialization |
|---|---|---|---|
| Group 1 (negative control) | + | + | Partial |
| Group 2 (positive control) | + | + | − |
| Group 3 (ZnO2-NPs-receiving group) | − | − | Complete |
| Group 4 (silver sulfadiazine-receiving group) | + | + | − |
Notes: −, absent; +, present.
Abbreviation: NPs, nanoparticles.